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In spite of the great number of observations which show the certainty of cardiovascular damage from smoking, the opinions on
that are not yet unanimous. There is a discrepancy that could be attributed to the lack of reproducible data particularly in some
epidemiological studies. On the contrary, experimental ﬁndings conducted on both animals and humans give evidence of exactly
reproducible results ofcardiovascularalterationsandamongthesethe course ofBloodPressure(BP).Findings identify an increase
in BP of active smokers or non-smokers exposed to passive smoking, while a lot of others refer a lowering of BP due to smoking.
Thisdiscrepancycouldbeexplainedasfollows.Initially,avasoconstrictionmediatedbynicotinecausesacutebut transientincrease
insystolicBP.This phaseis followed by a decrease inBP as a consequence ofdepressant eﬀects played chronicallyby nicotineitself.
Simultaneously,carbonmonoxideisactingdirectly onthearterial wallcausing,inthelongrun,structurallyirreversiblealterations.
At this time, there is a change in BP that increases again, and often constantly, its levels following chronic exposure. Changes in
response to antihypertensive drugs have been observed in hypertensive smokers since smoking inﬂuences metabolic steps of the
drugs.
1.Introduction
Tobacco smoke is a term indicating cigarette smoking, cigar
smoking, and pipe smoking. Usually, the main reports
concerning the relationship between smoking and cardio-
vascular alterations are attributed to cigarette smoking since
systematic studies on the harm caused by pipe and cigars are
yet lacking.
There are a lot of reports that identify cardiovascular
system as one of the major target organs for smoking [1–
12]. Either active or passive exposure to smoking causes
damage to the heart and blood vessels although pathological
mechanisms of damage may diﬀer with regards to the type
of action but not for that is concerning chemical toxics
responsible of the alterations [13–30].
I ns p i t eo ft h eg r e a tn u m b e ro fo b s e r v a t i o n sw h i c h
show the certainty of cardiovascular damage from smoking,
the opinions are not yet unanimous. There is a discrep-
ancy that could be attributed to the lack of reproducible
data particularly in some epidemiological studies. On the
contrary, experimental ﬁndings conducted on both animals
and humans give evidence of exactly reproducible results of
cardiovascular alterations.
Adverse eﬀects on the heart and vessels are mediated by
manychemicalcompoundsthatareusuallyconcentratedand
condensed into tobacco mixtures [23]. Over 4000 chemicals
have been identiﬁed in smoke, and a large majority of these
have carcinogenic and/or negative cardiovascular eﬀects in
humans and animals. Chemical compounds of smoking
cause both structural and functional alterations of heart
and blood vessels, although with diﬀerent results which are
depending on several factors related to the type of smoking,
environment, and subject exposed.
Worldwide, more than 3 million people currently die
each year from smoking, half of them before the age of 70,
an enormous human cost, and more than one and third have
cardiovascular events that often determine permanent dis-
abilityofaﬀectedsubjects[24,25].There are more than 1 bil-
lion smokers in the world with an increased/decreased/again
increased smoking habit.
Main cardiovascular diseases related tocigarette smoking
are listed in Table 1.2 Cardiology Research and Practice
Table 1: Main cardiovascular diseases related to cigarette smoking.
Coronary artery disease
Stroke and cerebrovascular disease
Peripheral artery disease
Aortic aneurysm
Hypertension
Heart failure
Arrhythmias
Endothelial dysfunction
Atherosclerosis
Among cardiovascular parameters, blood pressure (BP)
is adversely inﬂuenced by tobacco smoke with a high rate
by a mechanism yet under discussion. In addition, it is
not clear if smoking exposure causes a rise or reduction
of blood pressure and, otherwise, also if the occurrence of
hypertension in smokers is a consequence of the greatest
number of hypertensive people independently from smok-
ing, or smoking actively contributes to changes in BP.
The purpose of this paper is to discuss those results that
havebeenreachedbytheanalysisontherelationshipbetween
smoking and BP in both smokers and nonsmokers who were
passively exposed. The possible interference of smoking on
the eﬀects of the most used antihypertensive drugs is also
treated.
2.BloodPressureinActiveSmokers
Active smokers can display BP values which vary widely
accordingtoagreatnumberofindividual,racial,andlifestyle
factors. Moreover, changes in BP have been documented in
the same smoker while he is smoking a cigarette or not.
While a smoker is actively smoking, transiently sympathetic
responses, which acutely raise BP levels, usually occur.
Reports emphasize thathypertension orhypotensioncan
be associated with cigarette smoking in active smokers but
there is no evidence on the BP measures whether smoking
was lacking.
Some ﬁndings [31, 32] identiﬁed that cigarette smoking
in males was inversely related to systolic BP with a reduction
of 1.3mmHg in 1.1% of light smokers, 3.8mmHg in 3.1% of
moderate smokers, and 4.6mmHg in 3.7% of heavy smokers
whentheseindividualswerecomparedtononsmokers.There
was no clear relation with diastolic blood pressure. This
ﬁnding was conducted in an oriental population enrolled
in the study, but also in Western countries blood pressure
reduction was observed primarily in young smokers [32].
Inaddition,epidemiologicsurveys[33–41],althoughnot
all, demonstrated that individuals who smoked a diﬀerent
number of cigarettes had lower blood pressure than that
of non-smokers. Such a characteristic occurred in males,
females, adolescents, adults, and diﬀerent races. However,
this observation was attributed primarily to chronic smok-
ing. Associated loss in body weight of active smokers
contributes to lowering BP.
Table 2: Cardiovascular parameters particularly involved in smok-
ers.
Systolic BP
Heart rate
Endothelium-dependent vasodilation
Such data contrast strongly with the results obtained in
active smokers while they are smoking a cigarette as well as
in dated chronic smokers [32, 42–45].
These individuals display an evident increase in blood
pressure that seems to be clearly related to the toxic eﬀects of
nicotineand carbonmonoxideofacutetypebut,particularly
forthatconcernscarbonmonoxide,alsoofchronic typewith
structural arterial lesions associated. Structural alterations,
in the run, tend to change the behaviour of BP that becomes
irreversibly elevated although it was starting from increased
levels initially responsive to smoking cessation.
Nowadays, there is evidence that changes in vascular wall
begin as early as a smoker begins with smoking but they are
of no estimation because of masked damage, as that will be
described ahead.
3.Blood Pressurein Passive Smokers
Passive smokers display diﬀerent levels of BP depending on
the type and duration of exposure to environmental tobacco
smoke.
Increased levels of BP, particularly systolic BP, usually
follow acute but transient exposure [46]. Occasionally, there
is evidence of hypotension followed, however, by stable
hypertension in those individuals exposed for long time to
passive smoking even if exposure occurs irregularly.
Some conceptsare worthy to be clariﬁed to better under-
stand this occurrence.
An obvious consideration is that acute but transient
exposure to passive smoking of a non-smoker individual
makes him susceptible of main smoking compounds, pri-
marily nicotine but also carbon monoxide, which have,
initially, hypertensive eﬀects directly or indirectly through-
out adrenergic and sympathetic stimulation on arterial bed.
Similarly, increased heart rate can, usually, be identiﬁed.
Prolonging the exposure, these parameters [1–3, 5, 17, 18]
meet some changes which depend on a large number of
factors related to cardiovascular parameters. They inﬂuence
diﬀerently BP levels at the end of isolated acute exposure.
Physiology, biochemical characteristics and lifestyle interfere
with BP in exposed individuals. Table 2 shows the main
cardiovascular parameters involved.
Baseline levels usually tend to be reached after the
exposure in a variable but short time and adrenergic and
sympathetic proﬁle of the individual also contributesto that.
Finally, lifestyle is a strong positive or adverse factor to
restore cardiovascular parameters, particularly systolic blood
pressure, according to respectively regular physical exercise
performed by the individual or lacking that.Cardiology Research and Practice 3
BP is a clinical parameter of easy assessment and often
linked to endothelial dysfunction. Such a statement is partic-
ularly true for the essential hypertension [47, 48]. Moreover,
smoking and endothelial dysfunction are closely related in
passive smokers [19].
The acute response of BP to environmental tobacco
smoke would seem to determine an increase in systolic BP
levels in some reports [49, 50], whereas others [51]d i dn o t
concludefor this statement.
The possible hypothesis by which smoking compounds
inﬂuence BP could be explained as follows. Initially, a vaso-
constriction mechanism mediated by nicotine causes acute
buttransient increase in systolicBP. Thisphase isfollowedby
adecreaseinBPasaconsequenceofdepressanteﬀectsplayed
chronically by nicotine. Simultaneously, carbon monoxide is
acting directly on the arterial wall causing, in the long run,
structurally irreversible alterations. At this time, there is a
change in BP that increases again, and often constantly, its
levels [29]. Such a hypothesis explains BP changes following
chronic exposure. On the contrary, acute exposure to passive
smoking determines a transient increase in systolic BP due
to a combined eﬀect of nicotine that acts by endothe-
lial dysfunction and sympathetic stimulation, and carbon
monoxide which exerts its toxic eﬀects directly [52–55].
Increased systolic BP after acute exposure to passive smoking
was found also by Mahmud and Feely [56], whereas Leone
and Corsini [57] documented a decrease in BP following
repeated acute exposure to passive smoking. Decrease in
BP was proportional to the increase in carboxyhemoglobin
concentrations. Diastolic BP would seem to be aﬀected
weakly by environmental tobacco smoke exposure.
These observations identify no uniform course of blood
pressure in both active smokers and non-smokers exposed
and that concept needs to be clariﬁed by the hypothesis of
masked cardiovascular damage.
4.Masked CardiovascularDamage
The phenomenon of masked hypertension from smoking
was, ﬁrstly, described by Leone et al. [32]a sa ne x p l a n a t o r y
hypothesis of why no unanimous opinion existed on the
relationship between cigarette smoking and BP. In the time,
that phenomenon has found scientiﬁc support.
From up to here discussed data, a signiﬁcant observation
emerges: a diﬀerent response characterizes BP in actively or
passively exposed smokers due to the fact that the parameter
is assessed immediately after an acute exposure to environ-
mental tobacco smoke or after a chronic and prolonged
exposure. Acute exposure is followed by a transient but
signiﬁcant increase in systolic BP, whereas chronic exposure
may be followed by reduced or increased BP depending on
the presence of reversible or irreversible alterations of the
arterial wall caused by smoking compounds, particularly
carbon monoxide. These alterations are, for a variable time,
masked by the paralyzing action exerted by nicotine on
ganglionic ends that follows initial stimulation.
Acute exposure to passive smoking inﬂuences adversely
either blood vessel dilation since there is a reduced release of
nitric oxide, or arterial stiﬀness. Consequently, an increase
in BP [33, 45, 47, 48] is observed. These changes on
arterial stiﬀness, and then, BP usually occur before they are
clinically manifested [16] and are greater than those seen
when a smoker smokes a single cigarette. Although this type
of changes aﬀecting BP is, usually, proven lately, there is
evidence, however, that it begins acutely while an individual
smokes [14].
In conclusion, even if assessing systolic BP immediately
after environmental smoking exposure may be diﬃcult
unless in experimental ﬁndings, one cannot deny its increase
and, consequently, its interpretation as a marker of smoking
exposure.
As already described, nicotine may mask the eﬀects of
carbon monoxide on arterial wall for a long time. Adverse
eﬀects, usually, will appear when they will be of structurally
severe degree so that to induce stable hypertension.
5.AntihypertensiveDrugs
A large number of smoker individuals, primarily aged heavy
smokers, use antihypertensive drugs to ﬁght hypertension
similarly to that occurs in hypertensive non-smokers.
Often some of these drugs meet a change in their
mechanism of action because of a close interaction with the
main compounds of tobacco smoke, particularly nicotine
and its metabolites.
Of the main classes of antihypertensive drugs (Table 3),
beta-blockers feel primarily the adverse eﬀect of smoking
sincesmokingcompoundsinﬂuenceadverselytheactionand
eﬃcacy of beta-blocker drugs through a complex number
of eﬀects that involve metabolic response of adrenergic and
sympathetic system [58–60].
Beta-blockershavebeenshowntobelesseﬀectivetoﬁght
elevated BP and heart rate in habitual smokers compared
with non-smokers in two large-scale epidemiologicalsurveys
[61, 62].
Metabolic changes in response to propranolol infusion
have been observed particularly in elderly since physio-
logically autonomic nervous system meets an impairment
of diﬀerent degree and is, also, adversely inﬂuenced by
exposure tosmoking inagedpeople[63].Inaddition,thereis
evidence that the sensitivity of baroreceptor reﬂex in elderly
is impaired with a decrease in its function [64, 65]. The
decrease in sensitivity of baroreceptors is usually interpreted
as a consequence of increased aortic stiﬀness.
A study analyzed the eﬀect of aging on metabolic
steps of beta-adrenergic system [66]. It demonstrated that
isoproterenol that is able to increase signiﬁcantly heart rate
and BP needed higher concentrations to raise heart rate
of 25 beats per minute and the dose of propranolol that
reducedusually heart rate response was poorly eﬀective.This
eﬀect would seem to be related to a metabolic change in the
reactivity of catecholamine receptors [67].
More recent ﬁndings [68] have shown that third gen-
eration beta-1-adrenoceptor antagonists acting by an endo-
thelium-dependent vasodilatory mechanism, like nebivolol,
can reduce the adverse eﬀects of smoking and have a positive4 Cardiology Research and Practice
Table 3: Commonclasses of antihypertensive drugs and their response to smoking.
Drug Mechanism of action Response to smoking
Beta-blockers Inhibition beta 1 receptors Highly reduced (+++)
ACE-Inhibitors Blocked conversion Angiotensin 1 to Angiotensin II Highly reduced (+++)
Calcium Antagonists Block entry of calcium into vascular smooth cells Reduced (++/−)
Diuretics Decreased body sodium and extracellular ﬂuid volume Highly reduced (+++)
Angiotensin receptor blockers Block AT1 receptor not yet known (−− /+ ?)
+++:strongest reduction
++/−: moderate reduction
+: mildreduction
−− /+ : increase
? :not yet established.
action on endothelial function that was, however, limited
only to light smokers.
ACE-inhibitors are drugs largely used to reduce hy-
pertension since they interfere with the conversion of
angiotensin I to artery-constricting angiotensin II, the
strongest known vasoconstrictor. Blocking the production
of angiotensin II results in arterial vasodilation followed by
reduction in BP. ACE-inhibitors currently are recommended
as ﬁrst-line therapy for hypertension in certain patient
populations, primarily diabetic individuals, because of their
safety and eﬃcacy.
There is evidencethat cigarette smoking reduces dramat-
ically the beneﬁts of ACE inhibitors in treated hypertensive
people. Moreover, the response to ACE inhibitors of some
groups of individuals with hypertension complicated pri-
marily by diabetic renal disease is as strongly impaired as
worsening of those symptoms which are usually improved
by using these drugs [69]. The onset of microalbuminuria
in diabetic patients would be related to smoking and
hyperglycemia.
Calcium antagonists are a class of antihypertensive drugs
that interfere with calcium metabolism at diﬀerent levels,
primarily calcium channels. They are currently used for
treating hypertension.
Usually, calcium deposits are found into the arterial wall
with an increase in their content associated particularly with
aging. Since cigarette smoking induces vasoconstriction and
a major incidence ofthrombi formation where calcium plays
a strong metabolic role, there is evidence that hypertensive
smokers could be usefully treated by vasodilators drugs
which antagonize calcium deposit [70]. Therefore, using
calcium antagonists in hypertensive smokers could be a
rationale intervention even if these drugs also are adversely
inﬂuenced by cigarette smoking. Preventive eﬀects against
the damage from smoking would be identiﬁed by using
calcium antagonists together with nitroglycerin in coronary
artery disease [70].
A strongly adverse metabolic relationship exists between
smoking and diuretics.
Diuretics are a complex class of drugs largely used for
the treatment of hypertension [71, 72]. With the exception
of the antagonists of aldosterone, the main mechanism of
actionofthesedrugsconsistsofinhibitingiontransportersin
the luminal membrane of the renal tubule. There is evidence
that most of the data concerning the hypotensive action of
diuretics may be explained by the analysis of thiazide-type
diuretic action. These drugs, which are used in the treatment
ofhypertension with a major rate than thatof otherdiuretics
and often in combination, act by sodium depletion or by a
direct vascular eﬀect independent of natriuresis [73].
Smoking inﬂuencesstrongly diuretic treatment of hyper-
tensive smokers since it exerts an adverse eﬀect on BP
loweringprimarilyduetonicotineaction.Itisknownbylong
time that eitherintravenous injection of nicotine or smoking
one or two cigarettes has similar antidiuretic action in men
[74].
Finally, little is known about the relationship between
Angiotensin receptor blockers and smoking. Indeed, large-
scale ﬁndings on this matter are yet lacking.
An experimental study [75] suggests a positive eﬀect of
Valsartan, anAngiotensinreceptorblocker,onthealterations
caused by smoking on vascular endothelium. The drug
prevented smoking from impairing acetylcholine vasodila-
tion. There was evidence that acute single-cigarette smoking
caused a dysfunction of endothelium-dependent, but not
endothelium-independent, vasodilation of rat cerebral vessel
invivo.Theeﬀectwasnotmimickedbyintravenousnicotine.
Therefore, Angiotensin 1 receptor blockade could prevent
smoking-induced impairment of endothelium-dependent
vasodilationalthoughlarge-scaleﬁndings areyetmissingand
experimental data should be obtained.
Described data undoubtedly demonstrate that all the
major classes of drugs commonly used for the treatment
of hypertension are adversely inﬂuenced by smoking and,
consequently, the goal of an eﬀective treatment could fail
in hypertensive smokers independently by the mechanism of
action or choice of antihypertensive drug.
6.Conclusion
Two basic concepts arise from the analysis of exposed data.
They match Pandora’s box of Greek mythology [76].
Pandora’sjarisaboxwhereallexistingevilsarecontained
inside, when it is closed by a lid, to do not harm individuals.
Therefore, there is an apparently good health. On the con-
trary, when the lid is removed all evils come out damaging
heavily humans.Cardiology Research and Practice 5
The ﬁrst concept to stress is the diﬀerent response of BP
tosmokingcompoundsthatdependsonthetypeofsmoking,
its duration, and onset of BP increase.
Initially, young smokers usually display normal or even
low values of BP with no evident signs of vascular damage
that, however, are beginning although not well evident clini-
cally. Therefore, it would seem an illogical suggestion to for-
bidsmokingtotheseindividualswhoare,apparently,ingood
health.OnecanconsiderthisstageasthatofclosedPandora’s
box which masks the damage contained inside the box. This
couldbealso identiﬁedasthestagewhere tobaccosmokeacts
asanapparentfriend ofBPbecauseofnormalorlowerlevels.
The phenomenon of masked hypertension by either
active or passive smoking well correlates the duration of
smoking exposure and onset of BP increase. A growing liter-
ature highlights the role of this occurrence [77, 78]. The evi-
dence now suggests that to improve BP, we require to forbid
absolutely smoking as early as it has begun. Indeed, masked
hypertension seems to be associated particularly with passive
smoking in a dose-related manner, and low physical activity,
increased heart rate, and postural haemodynamic reaction,
all eﬀects similar to those of sympathetic stimulation, may
be potential accelerators of that phenomenon. Therefore,
masked hypertension causes a type of damage that, patho-
logically, starts low and goes slow, but in progress, for many
years even in case of pharmacological treatment.
When vascular wall alterations are evident and, more
often, irreversible, open Pandora’s box releases all unman-
ageable eﬀects which become the structural substrate for
hypertensive alterations.This stagerepresents tobaccosmoke
that is acting as enemy of BP.
Secondly, when there is evidence of hypertension to be
treated, the response to antihypertensive drugs in smokers is
usually impaired since biochemical and metabolic interfer-
ence exists between cigarette smoking and antihypertensive
drugs, although some classes of antihypertensive drugs
would less the eﬀects of smoking.
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